Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.3081 | 0.3907 |
Brugia malayi | TAR-binding protein | 0.0061 | 0.5626 | 0.516 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.2951 | 0.4076 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3378 | 0.2673 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0044 | 0.3081 | 0.3198 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.3081 | 0.3907 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7886 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0.5626 | 0.6014 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.3081 | 0.4256 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0535 | 0.0679 |
Brugia malayi | RNA binding protein | 0.0061 | 0.5626 | 0.516 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.3081 | 0.3907 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0.5626 | 0.516 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0.5626 | 0.6014 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.3081 | 0.4256 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0044 | 0.3081 | 0.2344 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0535 | 0.0739 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.3818 | 0.4014 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5626 | 0.7135 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.3081 | 0.4256 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0.5626 | 0.7771 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3391 | 0.3541 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0.5626 | 0.7771 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5626 | 0.7135 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0535 | 0.0739 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0.5626 | 0.6014 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5626 | 0.7135 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0191 | 0.0242 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.2951 | 0.4076 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.3081 | 0.4256 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.724 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4163 | 0.4395 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.724 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5626 | 0.7135 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.5626 | 0.7135 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9228 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.122 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 63.0957 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.